Skip to content

OPTIMAl Endovascular Exclusion of Consecutive Patient High-risk Carotid Plaque Using the MicroNet Covered Stent

OPTIMAl Endovascular Exclusion of High-risk Carotid Plaque Using the CGuard™ Stent in Patients With Symptoms or Signs of Carotid Stenosis-related Brain Injury: IVUS Controlled Investigator Initiated Multcentric Multi-specialty Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04234854
Acronym
OPTIMA
Enrollment
200
Registered
2020-01-21
Start date
2020-01-31
Completion date
2023-03-31
Last updated
2021-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid Artery Diseases

Keywords

Stenting

Brief summary

Prospective, multicentric, multispecialty, international, open-label, single arm study using per-protocol intravascular ultrasound \[IVUS, 20MHz electronic phase-array transducer\] to document the procedure result of an effective plaque exclusion from the vessel lumen.

Detailed description

Investigator initiated, academic, single arm, open-label, non-randomized, prospective, multicenter, multispecialty trial of CGuard™ use in all-comer population of consecutive patients with carotid stenosis related cerebral symptoms (TIA, stroke, retinal TIA, retinal stroke) or signs of ipsilateral brain injury on MRI or CT imaging. The main objective of this observational study is to evaluate an incidence of residual plaque prolapse after carotid stenting using the study device. Study Rationale In conventional carotid stents, plaque prolapse (PP) on intravascular imaging had been determined to be strongly associated with new post-procedural diffusion-weighted magnetic resonance lesions on cerebral imaging and with increased ischaemic stroke incidence. A significant increase in PP susceptibility was observed with unstable carotid plaque, pointing to the limitations of conventional CAS in unstable carotid plaques, such as symptomatic and increased-spontaneous-symptoms-risk lesions. This is reflected in current guidelines that provide a higher recommendation class to surgical management (CEA) rather than CAS for symptomatic lesions. Circumstantial evidence indicates that the novel carotid stent covered with MicroNET (CGuard EPS) may be an optimal device for effective carotid plaque sequestration (that may be particularly relevant in high-risk plaques) - but no systematic study has been performed thus far. Because of the increasing evidence that not only clinical symptoms (that may be related to for instance the affection of dominant vs. non-dominant haemisphere) but also signs of ipisilateral cerebral infarct/s are a hallmark of high-risk plaque and are associated with adverse prognosis, and because that neurology increasingly uses the term symptomatic to refer to carotid stenosis associated with clinically silent ipisilateral cerebral infarct/s, the present study will enroll both patients with clinical symptoms of cerebral ischaemia in relation to carotid stenosis and those with (clinically silent) signs of ipsilateral injury such as ischemic focus/foci on CT or MRI/DW-MRI). As previously demonstrated, clinically significant/relevant PP is that depicted by IVUS (with angiography, on the one hand, being not sensitive enough and OCT, on the other, being possibly too sensitive).

Interventions

DIAGNOSTIC_TESTIntravascular Utrasound (IVUS) of Carotid Artery after implantation of CGuard stent

IVUS will be performed after stent postdilatation to determine the incidence of plaque prolapse. Additionally optimizing stent expansion with IVUS is left at operator discretion.

Sponsors

InspireMD
CollaboratorINDUSTRY
John Paul II Hospital, Krakow
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All consecutive patients with clinically symptomatic carotid stenosis , or carotid stenosis associated with ipisilateral cerebral ischemic infarct/s on CT or MRI/DWI imaging, referred and accepted by the study center for CAS as per local standard referral pathways and study center routine. * Patient informed consent to participate. * Patient accepts follow-up scheme and consents to follow-up visits.

Exclusion criteria

* Lack of indication to carotid revascularization as per current ESC/ESVS Guidelines, or any clinical or angiographic or other contraindication to CAS (such as renal failure defined as creatinine level \> 2.5 mg/dL or eGFR \<20 ml/kg min, or incompatibility with DAPT). * Surgery within the preceding 30 days or planned surgery within 30 days after CAS. * Life expectancy \<1 year (eg. neoplastic disease). * MI within 72h prior to CAS. * Known coagulopathy. * History of cerebral stroke with documented/known cause other than carotid disease. * Atrial fibrillation or flutter. * Any known cause for potential cerebral embolization different than carotid stenosis. * History of intracranial bleeding. * Any contraindications to as per IFU study device implantation.

Design outcomes

Primary

MeasureTime frameDescription
Freedom from plaque prolapseDuring index procedureFreedom from plaque prolapse defined as observation of plaque inside the stent lumen after completion of the CAS procedure by IVUS assessment (Kotsugi 2017).

Secondary

MeasureTime frameDescription
Procedural successDuring index procedurestent delivery and implantation in absence of an intra-procedural clinical major adverse event, with no more than 30% residual diameter stenosis by on-site QCA, and successful withdrawal of the stent delivery and neuroprotection system
IVUS interrogation successDuring index procedureIVUS interrogation with an effective IVUS probe removal in absence of any clinical complications
Endovascular lumen reconstructionDuring index procedureFreedom from plaque prolapse plus minimal in-stent area \>50% ICA reference area
Periprocedural MACCEUntil discharge or up to 24 hoursDeath, stroke, myocardial infarction until discharge or up to 24 hours
Any periprocedural complicationsUntil discharge or up to 24 hoursAny complications occurring until discharge or 24 hours whichever comes first
Ipsilateral stroke between 31 days and 12 months after the procedureBetween 31 days and 12 months after the procedureIpsilateral stroke between 31 days and 12 months after the procedure
Duplex UltraSound (DUS) at 30 days30 daysPeak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) recorded by Duplex Doppler at 30±5 days after the procedure
Duplex UltraSound (DUS) at 12 months12 monthsPeak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) recorded by Duplex Doppler at 12 months after the procedure
30 days MACCE30 daysDeath, stroke, myocardial infarction until 30 days

Countries

Poland

Contacts

Primary ContactPiotr Musialek, Prof.
p.musialek@szpitaljp2.krakow.pl+48126142287

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026